ABSTRACT
Alzheimer’s disease (AD) is a common and increasing societal problem due to the extending human lifespan. In males, loss of chromosome Y (LOY) in leukocytes is strongly associated with AD. We studied here DNA methylation and RNA expression in sorted monocytes and granulocytes with and without LOY from male AD patients. Through multi-omic analysis, we identified new candidate genes and confirmed the involvement of numerous genes previously associated with AD. Our findings highlight LOY-related differences in DNA methylation that occur in gene regulatory regions and are predominantly accompanied by down-regulation of affected genes. Specifically, we observed alterations in key genes involved in leukocyte differentiation: FLI1, involved in early hematopoiesis; RUNX1, essential for blood cell development; RARA, regulating gene expression in response to retinoic acid; CANX, crucial for protein folding; CEBPB, a transcription factor important for immune responses; and MYADM, implicated in cell adhesion and migration. Moreover, protein-protein interaction analysis in granulocytes identified that products of two of these genes, CANX and CEBPB, are key hub proteins. Thus, LOY appears to dysregulate genes involved in leukocyte differentiation and induce higher-level epigenetic changes. This research underscores the potential of multi-omic approaches in pure cell populations to uncover the molecular underpinnings of AD and reinforces the significance of LOY as a pathogenic factor in this disease. Overall, results support the hypothesis that age-related immune cell dysfunction contributes to AD development. Finally, our results link previous analysis showing impact of LOY on leukocyte differentiation, LOY-associated transcriptional dysregulation and GWAS studies of LOY.
Competing Interest Statement
J.P.D is a cofounder and shareholder in Cray Innovation AB. The remaining authors declare that they have no competing interests.
Funding Statement
This study was supported by grants from the Foundation for Polish Science under the International Research Agendas Programme (grant number MAB/2018 /6; co-financed by the European Union under the European Regional Development Fund), Swedish Heart-Lung Foundation (grant number 20210051), the Swedish Research Council (grant number 2020-02010), Swedish Cancer Society, Hjärnfonden, and Alzheimerfonden to J.P.D. Methylation profiling was performed by the SNP&SEQ Technology Platform in Uppsala, Sweden. The SNP&SEQ Technology Platform is part of the Science for Life Laboratory at Uppsala University and is supported as national infrastructure by the Swedish Research Council.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted according to the guidelines of the Declaration of Helsinki. The study was approved by the local research ethics committee in Uppsala, Sweden (Regionala Etikprövningsnämnden in Uppsala (EPN): Dnr 2005-244, Ö48-2005; Dnr 2013/350; Dnr 2015/092; Dnr 2015/458; Dnr 2015/458/2, the latter with update from 2018) and the Bioethical Committee of the Regional Medical Chamber in Kraków, Poland (No. 6/KBL/OIL/2014).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The DNA methylation data used in this study are available from the authors upon a reasonable request. The bulk RNA-seq datasets are available upon a reasonable request from the authors of the original publication (PMID: 33837451).
Abbreviations
- LOY
- loss of chromosome Y
- ROY
- retention of chromosome Y
- AD
- Alzheimer’s disease
- DMP
- differentially methylated probe
- DEG
- differentially expressed gene
- DMG
- differentially methylated gene
- TSS
- transcription start site
- LOAD
- late onset Alzheimer’s disease
- EOAD
- early onset Alzheimer’s disease
- RNA-seq bulk
- RNA sequencing
- PBMCs
- peripheral blood mononuclear cells
- mLRRY
- median Log R Ratio values of probes from the male-specific part of chromosome Y
- FACS
- fluorescence-activated cell sorting.
